Abstract
Pharmaceutical Patent AnalystVol. 4, No. 1 CommentaryAre the UK courts clamping down on 'evergreening' strategies for the extension of patent protection?Jodie AlbuttJodie AlbuttDehns, St Bride's House, 10 Salisbury Square, London, EC4Y 8JD, UK E-mail Address: mail@dehns.comSearch for more papers by this authorPublished Online:7 Jan 2015https://doi.org/10.4155/ppa.14.48AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: evergreeningextensionpatentsupplementary protection certificateReferences1 Hospira UK Ltd v Genentech Inc. EWHC 1094 (Pat) (2014).Google Scholar2 Genentech: EP1210115 (2000).Google Scholar3 Genentech: EP 1308455 (1999).Google Scholar4 Genentech: PCT/US96/12251 (1996).. Google Scholar5 Richter Gedeon Vegyeszeti Gyar RT: EP 1448207 (2002).Google Scholar6 Generics (UK) Ltd (t/a Mylan) v Richter Gedeon Vegyeszeti Gyar RT. EWHC 1666 (Pat) (2014).Google Scholar7 SPC Regulation No. 469/2009 of the European Parliament and of the Council of 6 May 2009.Google Scholar8 Sanofi: SPC/GB99/008 (1999).Crossref, Google Scholar9 Actavis Group v Sanofi (C443/12) (12/12/13).Google Scholar10 Supreme Court of India, Civil Appellate Jurisdiction, Civil Appeal Nos. 2706–2716 of 2013, Novartis AG v Union of India & Others, with Civil Appeals No. 2728 of 2013 Natco Pharma Ltd v Union of India and Others and Civil Appeal Nos. 2717–2727 of 2013 M/S Cancer Patients Aid Association v Union of India & Others.Google ScholarFiguresReferencesRelatedDetailsCited ByStability Indicating RP-HPLC Simultaneous Estimation of Hyoscine Butylbromide and Paracetamol in Tablets26 July 2021 | Pharmaceutical Chemistry Journal, Vol. 69 Vol. 4, No. 1 Follow us on social media for the latest updates Metrics Downloaded 100 times History Published online 7 January 2015 Published in print January 2015 Information© Future Science LtdKeywordsevergreeningextensionpatentsupplementary protection certificateFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
